A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

NCT03823339 · Completed

Last updated 2026-05-28

This study is testing how the medication Xultophy® affects blood sugar levels in adults with type 2 diabetes in the United Arab Emirates.

Status Completed The study has finished.

Type Observational

Participants 300 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-01 · est. completion 2020-12

Where 3 sites · United Arab Emirates

What this study is testing ClinicalTrials.gov NCT03823339 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Xultophy® works in patients with type 2 diabetes. The participants will get Xultophy® as prescribed to them by the study doctor. The study will last for about 26-34 weeks. The participants will be asked questions about their health and their diabetes treatment as part of their normal study doctor's appointment.

Treatments tested

Insulin degludec/liraglutide Drug

Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.

Main thing measured	Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03823339 ↗